Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody^® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium^®, December 8-11, 2020.